chr1-11228701-G-A
Variant names: 
Variant summary
Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1
The NM_004958.4(MTOR):c.2997C>T(p.Asn999Asn) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.728 in 1,613,694 control chromosomes in the GnomAD database, including 433,703 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
 Genomes: 𝑓 0.65   (  34109   hom.,  cov: 31) 
 Exomes 𝑓:  0.74   (  399594   hom.  ) 
Consequence
 MTOR
NM_004958.4 synonymous
NM_004958.4 synonymous
Scores
 2
Clinical Significance
Conservation
 PhyloP100:  -0.749  
Publications
67 publications found 
Genes affected
 MTOR  (HGNC:3942):  (mechanistic target of rapamycin kinase) The protein encoded by this gene belongs to a family of phosphatidylinositol kinase-related kinases. These kinases mediate cellular responses to stresses such as DNA damage and nutrient deprivation. This kinase is a component of two distinct complexes, mTORC1, which controls protein synthesis, cell growth and proliferation, and mTORC2, which is a regulator of the actin cytoskeleton, and promotes cell survival and cell cycle progression. This protein acts as the target for the cell-cycle arrest and immunosuppressive effects of the FKBP12-rapamycin complex. Inhibitors of mTOR are used in organ transplants as immunosuppressants, and are being evaluated for their therapeutic potential in SARS-CoV-2 infections. Mutations in this gene are associated with Smith-Kingsmore syndrome and somatic focal cortical dysplasia type II. The ANGPTL7 gene is located in an intron of this gene. [provided by RefSeq, Aug 2020] 
MTOR Gene-Disease associations (from GenCC):
- macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Illumina, Orphanet, Labcorp Genetics (formerly Invitae), G2P
- overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genesInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -21 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.48). 
BP6
Variant 1-11228701-G-A is Benign according to our data. Variant chr1-11228701-G-A is described in ClinVar as Benign. ClinVar VariationId is 1170840.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. 
BP7
Synonymous conserved (PhyloP=-0.749 with no splicing effect.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.89  is higher than 0.05. 
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes  0.649  AC: 98586AN: 151888Hom.:  34091  Cov.: 31 show subpopulations 
GnomAD3 genomes 
 AF: 
AC: 
98586
AN: 
151888
Hom.: 
Cov.: 
31
Gnomad AFR 
 AF: 
Gnomad AMI 
 AF: 
Gnomad AMR 
 AF: 
Gnomad ASJ 
 AF: 
Gnomad EAS 
 AF: 
Gnomad SAS 
 AF: 
Gnomad FIN 
 AF: 
Gnomad MID 
 AF: 
Gnomad NFE 
 AF: 
Gnomad OTH 
 AF: 
GnomAD2 exomes  AF:  0.751  AC: 188750AN: 251254 AF XY:  0.755   show subpopulations 
GnomAD2 exomes 
 AF: 
AC: 
188750
AN: 
251254
 AF XY: 
Gnomad AFR exome 
 AF: 
Gnomad AMR exome 
 AF: 
Gnomad ASJ exome 
 AF: 
Gnomad EAS exome 
 AF: 
Gnomad FIN exome 
 AF: 
Gnomad NFE exome 
 AF: 
Gnomad OTH exome 
 AF: 
GnomAD4 exome  AF:  0.736  AC: 1075646AN: 1461688Hom.:  399594  Cov.: 61 AF XY:  0.738  AC XY: 536691AN XY: 727158 show subpopulations 
GnomAD4 exome 
 AF: 
AC: 
1075646
AN: 
1461688
Hom.: 
Cov.: 
61
 AF XY: 
AC XY: 
536691
AN XY: 
727158
show subpopulations 
African (AFR) 
 AF: 
AC: 
12222
AN: 
33470
American (AMR) 
 AF: 
AC: 
38099
AN: 
44718
Ashkenazi Jewish (ASJ) 
 AF: 
AC: 
17170
AN: 
26136
East Asian (EAS) 
 AF: 
AC: 
35712
AN: 
39700
South Asian (SAS) 
 AF: 
AC: 
71040
AN: 
86256
European-Finnish (FIN) 
 AF: 
AC: 
39914
AN: 
53420
Middle Eastern (MID) 
 AF: 
AC: 
4214
AN: 
5748
European-Non Finnish (NFE) 
 AF: 
AC: 
813223
AN: 
1111850
Other (OTH) 
 AF: 
AC: 
44052
AN: 
60390
 Allele Balance Distribution 
 Red line indicates average allele balance 
 Average allele balance: 0.471 
Heterozygous variant carriers
 0 
 15610 
 31220 
 46829 
 62439 
 78049 
 0.00 
 0.20 
 0.40 
 0.60 
 0.80 
 0.95 
Allele balance
Age Distribution
Exome Het
Exome Hom
Variant carriers
 0 
 20064 
 40128 
 60192 
 80256 
 100320 
 <30 
 30-35 
 35-40 
 40-45 
 45-50 
 50-55 
 55-60 
 60-65 
 65-70 
 70-75 
 75-80 
 >80 
Age
GnomAD4 genome  0.649  AC: 98648AN: 152006Hom.:  34109  Cov.: 31 AF XY:  0.656  AC XY: 48775AN XY: 74322 show subpopulations 
GnomAD4 genome 
 AF: 
AC: 
98648
AN: 
152006
Hom.: 
Cov.: 
31
 AF XY: 
AC XY: 
48775
AN XY: 
74322
show subpopulations 
African (AFR) 
 AF: 
AC: 
16000
AN: 
41422
American (AMR) 
 AF: 
AC: 
11928
AN: 
15276
Ashkenazi Jewish (ASJ) 
 AF: 
AC: 
2273
AN: 
3468
East Asian (EAS) 
 AF: 
AC: 
4709
AN: 
5166
South Asian (SAS) 
 AF: 
AC: 
4006
AN: 
4820
European-Finnish (FIN) 
 AF: 
AC: 
7870
AN: 
10564
Middle Eastern (MID) 
 AF: 
AC: 
221
AN: 
294
European-Non Finnish (NFE) 
 AF: 
AC: 
49478
AN: 
67976
Other (OTH) 
 AF: 
AC: 
1479
AN: 
2114
 Allele Balance Distribution 
 Red line indicates average allele balance 
 Average allele balance: 0.502 
Heterozygous variant carriers
 0 
 1521 
 3043 
 4564 
 6086 
 7607 
 0.00 
 0.20 
 0.40 
 0.60 
 0.80 
 0.95 
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
 0 
 790 
 1580 
 2370 
 3160 
 3950 
 <30 
 30-35 
 35-40 
 40-45 
 45-50 
 50-55 
 55-60 
 60-65 
 65-70 
 70-75 
 75-80 
 >80 
Age
Alfa 
 AF: 
Hom.: 
Bravo 
 AF: 
Asia WGS 
 AF: 
AC: 
2970
AN: 
3478
EpiCase 
 AF: 
EpiControl 
 AF: 
ClinVar
Significance: Benign 
Submissions summary: Benign:6 
Revision: criteria provided, multiple submitters, no conflicts
LINK: link 
Submissions by phenotype
not provided    Benign:3 
Jul 06, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided
- -
Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
not specified    Benign:2 
-
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing
- -
-
Clinical Genetics, Academic Medical Center
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing
- -
Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome    Benign:1 
Sep 05, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Computational scores
Source: 
Name
Calibrated prediction
Score
Prediction
 BayesDel_noAF 
 Benign 
 DANN 
 Benign 
 PhyloP100 
Splicing
Name
Calibrated prediction
Score
Prediction
 SpliceAI score (max) 
Details are displayed if max score is > 0.2
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at 
Publications
 You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.